Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

The S&P 500 slipped 0.3 percent after briefly climbing to the edge of its record earlier in the morning. The Dow Jones ...

NEW YORK (AP) — Stocks are rising on Wall Street Thursday, even as President Donald Trump’s latest tariffs kicked into effect ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

The iPhone maker's shares [rallied for a second day]( ...

Analysts delivered mixed verdicts on Eli Lilly after the drugmaker released late-stage trial results for its investigational ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Emmy Nominees In Comedy Casting Sound Off On Self Tapes, Future Of Their Jobs & Whether Trump's Assault On DEI Should Worry Hollywood ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...